GB00B0LCW083
GB00B0LCW083
HIKMA PHARMACEUTICALS PLC ORD S
Loading chart...
Pure Price Volatility Risk (Market Swings)
The business itself is financially solid (Financial Health 80/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±28.3% p.a.) and steep historical drawdowns.
Volatility Risk
Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.
Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta
Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.7x).
Beta (Market Relation)
0.65x
DefensiveVolatility (5Y p.a.)
28.3% p.a.
5-Year HorizonMax Drawdown (5Y)
-51.9%
5-Year HorizonSharpe Ratio
-0.34
Return / RiskSpeculative / High Risk: Score Basis:
Multi-Horizon Risk & Performance Matrix
Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.
High Volatility
Timeframe | Volatility (p.a.) | Max Drawdown | Sharpe Ratio | Return (p.a.) |
|---|---|---|---|---|
| 1 Year | — | — | — | -12.5% |
| 3 Years | 27.7% | -49.1% | -0.35 | -7.3% |
| 5 Years | 28.3% | -51.9% | -0.34 | -7.2% |
| 10 Years | 31.2% | -62.8% | -0.15 | -2.2% |
Automated Risk & Health Notes (Red Flags)
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (28.3% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -62.8% in the extended horizon.
Corporate Governance & ISS Scores
Overall Governance Risk
3 ISS Score: 3 / 10
Audit Risk
6 ISS Score: 6 / 10
Board Risk
4 ISS Score: 4 / 10
Short Ratio
-